Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Amelito B Malapira

Neurology Virginia Beach, VA Medical Doctor

NPI 1710914239 CMS profile 168018

1950 Glenn Mitchell Dr, Suite 200, Virginia Beach, VA 23456

Open in the dashboard

General payments

$227,288

288 records reported · program years 2019–2024

Research payments

$2,735

Paid to them · 1 record reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$431,179 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Amelito B Malapira of Virginia Beach, VA is reported in the CMS Open Payments database as having received $227,288 across 288 general payments and $2,735 in research payments paid to them. Separately, studies naming them as principal investigator received $431,179 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $4,686 6
2023 General $1,800 2
2022 General $16,454 17
2021 General $64,339 67
2021 Research $2,735 1
2020 General $64,886 70
2019 General $75,123 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amelito B Malapira
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Amelito B Malapira were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Amelito B Malapira Neurology median Middle half National median
2019 $75,123 $474 $118–$2,177 $163
2020 $64,886 $367 $82–$2,309 $114
2021 $64,339 $438 $104–$2,547 $132
2022 $16,454 $442 $103–$2,388 $149
2023 $1,800 $464 $119–$2,312 $160
2024 $4,686 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Allergan Inc. $93,921 85 payments
  2. Lilly USA, LLC $71,418 134 payments
  3. AbbVie, Inc. $36,937 35 payments
  4. Biohaven Pharmaceuticals, Inc. $13,047 19 payments
  5. Biodelivery Sciences International, Inc. $7,572 11 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $4,394 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $178,343 118 payments
  2. Consulting Fee $18,925 5 payments
  3. Travel and Lodging $18,564 55 payments
  4. Honoraria $6,500 1 payment
  5. Food and Beverage $4,900 106 payments
  6. Grant $42 1 payment
  7. Education $15 2 payments
Products named General payments · program years 2019–2024
  1. UBRELVY Neuroscience $45,191 44 payments
  2. EMGALITY $40,806 49 payments
  3. BOTOX Neuroscience $34,816 24 payments
  4. UBRELVY Neuroscience $23,592 19 payments
  5. BOTOX Neuroscience $19,547 18 payments
  6. NURTEC ODT $17,441 23 payments
  7. REYVOW $13,888 20 payments
  8. ELYXYB - CELECOXIB $7,572 11 payments
  9. BOTOX Anti-Migraine $7,435 6 payments
  10. BOTOX Botox Therapeutic $154 3 payments
  11. Other $122 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Eli Lilly and Company $2,735 1 payment

Records

289 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record